LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 266 filers reported holding LIGAND PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 4.64 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $3,430,000 | -58.6% | 34,489 | -60.4% | 0.53% | -66.0% |
Q3 2020 | $8,292,000 | -40.7% | 86,995 | -30.5% | 1.57% | -46.1% |
Q2 2020 | $13,993,000 | +26.8% | 125,101 | -17.6% | 2.92% | +17.9% |
Q1 2020 | $11,038,000 | +90.1% | 151,792 | +172.7% | 2.47% | +158.0% |
Q4 2019 | $5,806,000 | +78.1% | 55,672 | +70.0% | 0.96% | +65.6% |
Q3 2019 | $3,260,000 | -52.3% | 32,748 | -45.3% | 0.58% | -50.1% |
Q2 2019 | $6,831,000 | +12.0% | 59,838 | +23.3% | 1.16% | +8.2% |
Q1 2019 | $6,101,000 | -43.9% | 48,536 | -39.5% | 1.07% | -53.0% |
Q4 2018 | $10,881,000 | +2.8% | 80,183 | +108.0% | 2.28% | +31.7% |
Q3 2018 | $10,584,000 | +2.6% | 38,557 | -22.6% | 1.73% | -0.9% |
Q2 2018 | $10,316,000 | +23.6% | 49,793 | -1.4% | 1.75% | +10.2% |
Q1 2018 | $8,343,000 | +24.8% | 50,514 | +3.4% | 1.58% | +26.0% |
Q4 2017 | $6,687,000 | -36.8% | 48,837 | -37.2% | 1.26% | -40.5% |
Q3 2017 | $10,588,000 | +47.4% | 77,767 | +31.5% | 2.12% | +30.0% |
Q2 2017 | $7,181,000 | – | 59,155 | – | 1.63% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knott David M Jr | 115,000 | $7,682 | 2.90% |
VILLERE ST DENIS J & CO LLC | 483,347 | $32,287 | 2.52% |
Monarch Partners Asset Management LLC | 62,327 | $4,163,444 | 1.23% |
Chicago Capital, LLC | 319,054 | $21,312,820 | 1.18% |
RICE HALL JAMES & ASSOCIATES, LLC | 285,634 | $19,080,351 | 1.09% |
Stephens Investment Management Group LLC | 454,416 | $30,713,977 | 0.56% |
Smith, Graham & Co., Investment Advisors, LP | 65,372 | $4,366,850 | 0.53% |
WOODSTOCK CORP | 55,014 | $3,674,935 | 0.49% |
Court Place Advisors, LLC | 15,533 | $1,037,605 | 0.38% |
ISTHMUS PARTNERS, LLC | 19,830 | $1,324,644 | 0.20% |